Investors are often attracted to unprofitable companies like Salesforce.com for their growth potential. However, it's crucial to consider if a company's cash burn rate is sustainable. Keros Therapeutics seems to have a healthy cash runway, but investors should monitor its cash burn and growth trajectory.